<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peroxisome proliferator-activated receptors (PPARs) play key roles in the regulation of energy homeostasis and <z:mp ids='MP_0001845'>inflammation</z:mp>, and <z:chebi fb="4" ids="48705">agonists</z:chebi> of PPARalpha and -gamma are currently used therapeutically </plain></SENT>
<SENT sid="1" pm="."><plain>Fibrates, first used in the 1970s for their <z:chebi fb="23" ids="18059">lipid</z:chebi>-modifying properties, were later shown to activate PPARalpha </plain></SENT>
<SENT sid="2" pm="."><plain>These agents lower plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and <z:chebi fb="1" ids="39027">VLDL</z:chebi> particles and increase <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, effects that are associated with cardiovascular benefit </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi>, acting via PPARgamma, influence free fatty acid flux and thus reduce <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain>PPARgamma <z:chebi fb="4" ids="48705">agonists</z:chebi> are therefore used to treat type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>PPARalpha and -gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> also affect <z:mp ids='MP_0001845'>inflammation</z:mp>, vascular function, and vascular remodeling </plain></SENT>
<SENT sid="6" pm="."><plain>As knowledge of the pleiotropic effects of these agents advances, further potential indications are being revealed, including roles in the management of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Dual PPARalpha/gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> (currently in development) look set to combine the properties of <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> and fibrates, and they hold considerable promise for improving the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and providing an effective therapeutic option for treating the multifactorial components of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation </plain></SENT>
</text></document>